Science Explorer Back to mapMap

Most cited papers from Merck KGaA, Darmstadt (Germany)

What are the most cited papers from Merck KGaA, Darmstadt (Germany)?

The most cited paper from Merck KGaA, Darmstadt (Germany) is "2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative" (Daniel Aletaha et al., 2010), with 9,731 citations. Next come "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)" (6,023) and "Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck" (5,137).

Showing 50 of 60 papers. Every paper with more than 501 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative Daniel Aletaha et al. · Arthritis & Rheumatism Open access 10 Aug 2010 9,731
2 Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors 2 Jan 2016 6,023
3 Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine Open access 8 Feb 2006 5,137
4 Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine Open access 21 Jul 2004 5,071
5 Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine Open access Apr 2009 3,899
6 Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera et al. · New England Journal of Medicine Open access 10 Sep 2008 3,762
7 Meta-analyses involving cross-over trials: methodological issues Diana Ruth Elbourne, Douglas G. Altman, Julian P. T. Higgins et al. · International Journal of Epidemiology Open access Feb 2002 2,318
8 Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand Jian-Ping Xiong, Thilo Stehle, Rongguang Zhang et al. · Science 5 Apr 2002 1,616
9 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet Open access May 2009 1,360
10 Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Patrício Godoy et al. · Archives of Toxicology Open access Aug 2013 1,303
11 Crystal Structure of the Extracellular Segment of Integrin αVβ3 Jian-Ping Xiong, Thilo Stehle, Beate Diefenbach et al. · Science Open access 12 Oct 2001 1,285
12 Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Howard L. Kaufman, Jeffery Scott Russell, Omid Hamid et al. · The Lancet Oncology Open access 7 Sep 2016 1,235
13 Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Roger Stupp et al. · The Lancet Oncology Open access 19 Aug 2014 1,053
14 NCCN Guidelines Insights: Colon Cancer, Version 2.2018 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network Open access Apr 2018 1,045
15 Interactions between Autophagy Receptors and Ubiquitin-like Proteins Form the Molecular Basis for Selective Autophagy Vladimir V. Rogov, Volker Dötsch, Terje Johansen et al. · Molecular Cell Open access 2014 1,018
16 Metabolism and Kinetics of Bisphenol A in Humans at Low Doses Following Oral Administration Wolfgang Völkel, Thomas Colnot, György András Csanády et al. · Chemical Research in Toxicology 24 Sep 2002 1,006
17 Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology Open access 25 Apr 2017 998
18 On the use of vinylene carbonate (VC) as an additive to electrolyte solutions for Li-ion batteries Doron Aurbach, K. Gamolsky, Boris Markovsky et al. · Electrochimica Acta Feb 2002 992
19 Nonradiating anapole modes in dielectric nanoparticles Andrey E. Miroshnichenko, Andrey B. Evlyukhin, Yefeng Yu et al. · Nature Communications Open access 27 Aug 2015 992
20 Minimum Information about a Biosynthetic Gene cluster Marnix H. Medema et al. · Nature Chemical Biology Open access154 authors 18 Aug 2015 927
21 The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin Bernd Greiner, Michel F Eichelbaum, Péter Fritz et al. · Journal of Clinical Investigation Open access 15 Jul 1999 921
22 Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations Paul K. Paik et al. · New England Journal of Medicine Open access 28 May 2020 891
23 International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors Françoise Bachelerie et al. · Pharmacological Reviews Open access 11 Nov 2013 872
24 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung et al. · The Lancet Oncology Open access 17 Apr 2013 842
25 N -Methylated Cyclic RGD Peptides as Highly Active and Selective α V β 3 Integrin Antagonists Michael A. Dechantsreiter, Eckart Planker, Barbara Mathä et al. · Journal of Medicinal Chemistry Open access 24 Jul 1999 840
26 Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Annals of Oncology Open access 12 Jan 2011 786
27 Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Luc Yves Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment Open access 23 Oct 2017 764
28 LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins Manfred Hendlich, Friedrich Rippmann, Gerhard Barnickel · Journal of Molecular Graphics and Modelling Dec 1997 752
29 Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies Nicola J. Hewitt, María José Gómez Lechón, J. Brian Houston et al. · Drug Metabolism Reviews 2007 735
30 Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Sabine Tejpar, Sebastian Stintzing, Fortunato Ciardiello et al. · JAMA Oncology Open access 10 Oct 2016 730
31 PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules Daan M. F. van Aalten, R. P. Bywater, J. B. C. Findlay et al. · Journal of Computer-Aided Molecular Design Jun 1996 721
32 MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman et al. · Journal of Clinical Oncology Open access 5 Jan 2016 706
33 Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton Mira Krendel, Frank T. Zenke, Gary Bokoch · Nature Cell Biology 25 Mar 2002 685
34 Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials Chantal Quinten, Corneel Coens, Murielle E.L. Mauer et al. · The Lancet Oncology Review 19 Aug 2009 662
35 Proliferative and Nonproliferative Lesions of the Rat and Mouse Hepatobiliary System Bob Thoolen, Robert R. Maronpot, Takanori Harada et al. · Toxicologic Pathology Open access Dec 2010 659
36 Common Electroanalytical Behavior of Li Intercalation Processes into Graphite and Transition Metal Oxides Doron Aurbach, Mikhail D. Levi, Elena Levi et al. · Journal of The Electrochemical Society Sep 1998 652
37 Massenspektrometrie B. Güssregen · Springer Reference Medizin Book chapter 2019 649
38 Proteinase K from Tritirachium album Limber W. Ebeling, N. Hennrich, Michael Klockow et al. · European Journal of Biochemistry Aug 1974 648
39 Solid‐State Electrochemical Kinetics of Li‐Ion Intercalation into Li1 − x CoO2: Simultaneous Application of Electroanalytical Techniques SSCV, PITT, and EIS Mikhael D. Levi, Gregory Salitra, Boris Markovsky et al. · Journal of The Electrochemical Society Apr 1999 644
40 Randomized, comparative study of interferon β-1a treatment regimens in MS HILLEL S. PANITCH, Douglas S. Goodin, G. Francis et al. · Neurology 26 Nov 2002 638
41 DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment Andrea Volkamer, Daniel Kühn, Friedrich Rippmann et al. · Bioinformatics Open access 23 May 2012 625
42 Converting a Peptide into a Drug: Strategies to Improve Stability and Bioavailability Céline Adessi, Claudio Soto · Current Medicinal Chemistry May 2002 615
43 Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial Jacques P. Brown, Richard Lewis Prince, Chad L. Deal et al. · Journal of Bone and Mineral Research 16 Dec 2008 609
44 Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier et al. · European Journal of Cancer 23 Mar 2012 598
45 Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors Jason J. Luke, Jeffrey M. Lemons, Theodore G Karrison et al. · Journal of Clinical Oncology Open access 13 Feb 2018 597
46 Amyloid beta oligomers induce impairment of neuronal insulin receptors Weiqin Zhao, Fernanda G. De Felice, Sara J. Fernandez et al. · The FASEB Journal 24 Aug 2007 591
47 Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 Sarah Adler et al. · Archives of Toxicology Open access 30 Apr 2011 585
48 RANTES Deposition by Platelets Triggers Monocyte Arrest on Inflamed and Atherosclerotic Endothelium Philipp von Hundelshausen, Kim S. C. Weber, Yuqing Huo et al. · Circulation 3 Apr 2001 584
49 Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3Antagonists Roland Haubner, Rainer Gratias, Beate Diefenbach et al. · Journal of the American Chemical Society 1996 582
50 EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Robert Pirker, Jose R. Pereira, Joachim von Pawel et al. · The Lancet Oncology 5 Nov 2011 580

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.